메뉴 건너뛰기




Volumn 12, Issue 2, 1999, Pages 135-139

Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection

Author keywords

Intraabdominal infection; Pharmacodynamic simulation; Trovafloxacin

Indexed keywords

ANTIBIOTIC AGENT; TROVAFLOXACIN;

EID: 0033042243     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00062-X     Document Type: Article
Times cited : (1)

References (20)
  • 1
    • 0029767419 scopus 로고    scopus 로고
    • Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species
    • (Suppl. 3)
    • Snydman D.R., McDermott L. Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species. Infect Dis Clin Pract. 5:1996;96-100. (Suppl. 3).
    • (1996) Infect Dis Clin Pract , vol.5 , pp. 96-100
    • Snydman, D.R.1    McDermott, L.2
  • 2
    • 0028096987 scopus 로고
    • In vitro activity of the new fluoroquinolone CP-99,219
    • Neu H.C., Chin N. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 38:1984;2615-2622.
    • (1984) Antimicrob Agents Chemother , vol.38 , pp. 2615-2622
    • Neu, H.C.1    Chin, N.2
  • 3
    • 0027999053 scopus 로고
    • Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin-tazobactam against 489 anaerobes
    • Spangler S.K., Jacobs M.R., Appelbaum P.C. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 38:1994;2471-2476.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 2471-2476
    • Spangler, S.K.1    Jacobs, M.R.2    Appelbaum, P.C.3
  • 4
    • 0029768777 scopus 로고    scopus 로고
    • Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis
    • (Suppl. 3)
    • Onderdonk A.B. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis. Infect Dis Clin Pract. 5:1996;S117-S119. (Suppl. 3).
    • (1996) Infect Dis Clin Pract , vol.5
    • Onderdonk, A.B.1
  • 5
    • 0031019078 scopus 로고    scopus 로고
    • In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteriodes fragilis and Escherichia coli
    • Thadepalli H.U., Reddy S.K., Chuah F., Thadepalli C., Malilay R.J., Polzer R. et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteriodes fragilis and Escherichia coli. Antimicrob Agents Chemother. 41:1997;583-586.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 583-586
    • Thadepalli, H.U.1    Reddy, S.K.2    Chuah, F.3    Thadepalli, C.4    Malilay, R.J.5    Polzer, R.6
  • 6
    • 0029805020 scopus 로고    scopus 로고
    • Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: In vitro pharmacodynamic simulation
    • Balcabao I.P., Aguilar L., Martín M., García Y., Dal-Ré R., Prieto J. Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: In vitro pharmacodynamic simulation. Antimicrob Agents Chemother. 40:1996;2904-2906.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 2904-2906
    • Balcabao, I.P.1    Aguilar, L.2    Martín, M.3    García, Y.4    Dal-Ré, R.5    Prieto, J.6
  • 7
    • 0031049862 scopus 로고    scopus 로고
    • In-vitro pharmacodynamic simulation of clavulanic acid concentrations on Staphylococcus aureus and Haemophilus influenzae β-lactamase activity
    • Martín M., Aguilar L., Balcabao I.P., Gómez-Lus M.L., Dal-Ré R., Prieto J. In-vitro pharmacodynamic simulation of clavulanic acid concentrations on Staphylococcus aureus and Haemophilus influenzae β-lactamase activity. J Antimicrob Chemother. 39:1997;290-292.
    • (1997) J Antimicrob Chemother , vol.39 , pp. 290-292
    • Martín, M.1    Aguilar, L.2    Balcabao, I.P.3    Gómez-Lus, M.L.4    Dal-Ré, R.5    Prieto, J.6
  • 8
    • 0003772229 scopus 로고
    • National Committee for Clinical Laboratory Standards. Approved standard. NCCLS document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA
    • National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility test for bacterial that grow aerobically. 3rd ed. Approved standard. NCCLS document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
    • (1993) Methods for Antimicrobial Susceptibility Test for Bacterial That Grow Aerobically. 3rd Ed.
  • 9
    • 0003634054 scopus 로고
    • National Committee for Clinical Laboratory Standards. Approved standard. NCCLS document M11-A3. National Committee for Clinical Laboratory Standards, Villanova, PA
    • National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 3rd ed. Approved standard. NCCLS document M11-A3. National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
    • (1993) Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 3rd Ed.
  • 10
    • 38249019977 scopus 로고
    • Assessing cidal activity of antimicrobial agents: Problems and pitfalls
    • Amsterdam D. Assessing cidal activity of antimicrobial agents: problems and pitfalls. Antimicrob Newsl. 7:1990;49-56.
    • (1990) Antimicrob Newsl , vol.7 , pp. 49-56
    • Amsterdam, D.1
  • 11
    • 38249014513 scopus 로고
    • The MIC: Myth and reality
    • Amsterdam D. The MIC: myth and reality. Antimicrob Newsl. 8:1992;9-16.
    • (1992) Antimicrob Newsl , vol.8 , pp. 9-16
    • Amsterdam, D.1
  • 12
    • 0029763343 scopus 로고    scopus 로고
    • Activity of the antibiotic CP-99,219 (trovafloxacin) in a mixed microflora growth system model of intraabdominal infections in humans
    • (Suppl. 3)
    • Ross R.A., Onderdonk A. Activity of the antibiotic CP-99,219 (trovafloxacin) in a mixed microflora growth system model of intraabdominal infections in humans. Infect Dis Clin Pract. 5:1996;S110-S112. (Suppl. 3).
    • (1996) Infect Dis Clin Pract , vol.5
    • Ross, R.A.1    Onderdonk, A.2
  • 14
    • 0031983331 scopus 로고    scopus 로고
    • Activity of trovafloxacin (with or without ampicillin-sulbactam) against Enterococci in an in vitro dynamic model of infection
    • Zinner S., Gilbert D., Dudley N. Activity of trovafloxacin (with or without ampicillin-sulbactam) against Enterococci in an in vitro dynamic model of infection. Antimicrob Agents Chemother. 42:1998;72-77.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 72-77
    • Zinner, S.1    Gilbert, D.2    Dudley, N.3
  • 17
    • 0025744732 scopus 로고
    • Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions
    • Cooper M.A., Andrews J.M., Wise R. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother. 28:1991;399-405.
    • (1991) J Antimicrob Chemother , vol.28 , pp. 399-405
    • Cooper, M.A.1    Andrews, J.M.2    Wise, R.3
  • 18
    • 0029784338 scopus 로고    scopus 로고
    • Bactericidal activity of trovafloxacin under anaerobic and aerobic conditions
    • (Suppl. 3)
    • Boswel F.J., Andrews J.M., Wise R. Bactericidal activity of trovafloxacin under anaerobic and aerobic conditions. Infect Dis Clin Pract. 5:1996;S113-S116. (Suppl. 3).
    • (1996) Infect Dis Clin Pract , vol.5
    • Boswel, F.J.1    Andrews, J.M.2    Wise, R.3
  • 19
    • 0024379695 scopus 로고
    • Effect of blood product medium supplements on the activity of cefotaxime and other cephalosporins against E. faecalis
    • Eliopoulos G.M., Reiszner E., . Willey S., Novick W.J., Moeleering R.C. Effect of blood product medium supplements on the activity of cefotaxime and other cephalosporins against E. faecalis. Diag Microbiol Infect Dis. 12:1989;149-156.
    • (1989) Diag Microbiol Infect Dis , vol.12 , pp. 149-156
    • Eliopoulos, G.M.1    Reiszner, E.2    Willey, S.3    Novick, W.J.4    Moeleering, R.C.5
  • 20
    • 0344901426 scopus 로고    scopus 로고
    • Comparisons of intravenous alatrofloxacin-to-oral trovafloxacin versus intravenous imipenem/cilastatin-to-oral amoxicillin/clavulanic acid for the treatment of complicated intra-abdominal infections
    • The intra-abdominal Infections Study Group. Poster M258. 10-13 May
    • Luke DR, The intra-abdominal Infections Study Group. Comparisons of intravenous alatrofloxacin-to-oral trovafloxacin versus intravenous imipenem/cilastatin-to-oral amoxicillin/clavulanic acid for the treatment of complicated intra-abdominal infections. Poster M258. 2nd European Congress of Chemotherapy and 7th Biennial Conference of Antiinfective Agents and Chemotherapy Hamburg, 10-13 May, 1998.
    • (1998) 2nd European Congress of Chemotherapy and 7th Biennial Conference of Antiinfective Agents and Chemotherapy Hamburg
    • Luke, D.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.